home / stock / polbf / polbf quote
Last: | $0.2269 |
---|---|
Change Percent: | 0.04% |
Open: | $0.2268 |
Close: | $0.2269 |
High: | $0.2269 |
Low: | $0.2268 |
Volume: | 3,384 |
Last Trade Date Time: | 05/07/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.2269 | $0.2268 | $0.2269 | $0.2269 | $0.2268 | 3,384 | 05-07-2024 |
$0.151 | $0.151 | $0.151 | $0.151 | $0.151 | 5,000 | 05-01-2024 |
$0.139 | $0.139 | $0.139 | $0.139 | $0.139 | 159 | 04-26-2024 |
$0.11 | $0.11 | $0.11 | $0.11 | $0.11 | 100 | 04-01-2024 |
$0.107 | $0.107 | $0.107 | $0.107 | $0.107 | 1,656 | 01-15-2024 |
$0.107 | $0.107 | $0.107 | $0.107 | $0.107 | 1,656 | 01-12-2024 |
$0.115 | $0 | $0.115 | $0 | $0 | 2 | 10-06-2023 |
$0.115 | $0 | $0.115 | $0 | $0 | 9,473 | 09-13-2023 |
$0.115 | $0 | $0.115 | $0 | $0 | 2 | 06-08-2023 |
$0.115 | $0 | $0.115 | $0 | $0 | 83 | 06-07-2023 |
$0.115 | $0.115 | $0.115 | $0.115 | $0.115 | 10,000 | 02-07-2023 |
$0.102 | $0.12045 | $0.102 | $0.12045 | $0.102 | 58,300 | 02-01-2023 |
$0.1001 | $0.105 | $0.1001 | $0.105 | $0.1001 | 5,000 | 01-31-2023 |
$0.073 | $0 | $0.073 | $0 | $0 | 7 | 01-24-2023 |
$0.073 | $0 | $0.073 | $0 | $0 | 7 | 12-29-2022 |
$0.073 | $0.073 | $0.073 | $0.073 | $0.073 | 100 | 12-20-2022 |
$0.115 | $0.115 | $0.115 | $0.115 | $0.115 | 2,500 | 12-02-2022 |
$0.121 | $0 | $0.121 | $0 | $0 | 1 | 11-28-2022 |
$0.121 | $0.121 | $0.121 | $0.121 | $0.121 | 100 | 11-22-2022 |
$0.121 | $0 | $0.121 | $0 | $0 | 1 | 11-18-2022 |
News, Short Squeeze, Breakout and More Instantly...
Poolbeg Pharma plc Ord GBP 0.0002 Company Name:
POLBF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief legal officer John McEvoy joins Proactive's Stephen Gunnion with news that POLB 001's Immuno-modulator II has received the fully granted patent from the US Patent Office. McEvoy explained the patent encompasses a class of d...
(NewsDirect) Poolbeg Pharma PLC CEO Jeremy Skillington and Tim Coté CEO of Silk Road Therapeutics join Proactive's Stephen Gunnion with details of an exclusive 12-month option agreement with Silk Road Therapeutics for Poolbeg to acquire a novel topical drug aimed at treating oral ulc...
Significant POLB 001 Patent Granted in United States Immunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering LONDON, UK / ACCESSWIRE / May 1, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF, 'Poolbeg' or the 'Company'), a biopharm...